Current Studies

Urine, vaginal and endocervical swab collection study to test a device for the detection of Chlamydia (CT), Gonorrhea (NG) and Trichomonas (TV).

ELIGIBILITY:       

• FEMALE PATIENTS 18 years and older
• Symptomatic or asymptomatic (i.e. table visits: problems, well women, etc.)
• NOT pregnant, 
• NOT had a pap within the last 2 months

Urine and vaginal swab collection study to test a device for the detection of Chlamydia (CT) and Gonorrhea (NG).

ELIGIBILITY:       

• FEMALE AND MALE PATIENTS 18 years and older
• Symptomatic or asymptomatic (i.e. table visits: problems, well women, etc.)
• NOT pregnant

Eligibility:

• Female subjects 18 years and older
• Negative pregnancy test
• Agree to use an approved method of contraception
• Have a history of recurrent VVC or yeast infection
• Must have an active VVC or yeast infection episode at the time of screening
• Willing and able to provide written informed consent
• Willing and able to comply with protocol requirements, instructions, and protocol-stated restrictions and be likely to complete the study as planned

*Subjects of non-childbearing potential must meet the requirements defined below:
• Pre-menopausal with documentation of surgical sterilization (i.e., hysterectomy,  bilateral tubal ligation, bilateral oophorectomy, or bilateral salpingectomy) at least 3 months prior to study entry.

• Post-menopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments.

Broken Condom? Didn't use anything?

ELIGIBILITY:

• Female subjects should be between 18 & 40 years old
• Must weigh over 176 pounds (80kg)
• Must have had unprotected intercourse within the last 72 hours

 *Free medication and financial compensation provided
 

We are recruiting PPSP patients who:

Are Female

Are 18 years and older.

Believe they have suspected or is symptomatic for Urinary Tract Infection (UTI).

Are willing to take investigative medications to treat their UTI (Study sponsored by GlaxoSmithKline Research)

Are willing to sign consents to participate in the study.

Are willing to participate in the study for a duration of approximately 28 days with 4 scheduled study visits.

Are of childbearing potential (WOCBP) and is not pregnant

Are willing to abstain from sexual activity for up to 2 weeks

Are willing to be paid at each scheduled study visit (summing up to $398 at end of study participation).  

 

This Phase III study’s aim is to evaluate the therapeutic response and clinical efficacy of oral gepotidacin compared to oral nitrofurantoin for acute cystitis(UTI) in adolescent and adult female participants.